Drug Interaction Study Between AZD3480 and Warfarin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin

NCT01214122

Pharmacokinetics Pharmacodynamics

WITHDRAWN PHASE1

Study to Investigate Safety and Tolerability of a Single Dose of AZD6482

NCT00688714

Antiplatelet Effect

COMPLETED PHASE1

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin

NCT03426033

Elevated Lipoprotein(a) Cardiovascular Diseases

COMPLETED PHASE1

Bleeding Time Study With AZD6482, Clopidogrel and ASA

NCT00853450

Antiplatelet Effect

COMPLETED PHASE1

The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack

NCT02144831

Transient Ischemic Attacks Minor Stroke

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

AZD3480 + warfarin

Group Type EXPERIMENTAL

AZD3480

Intervention Type DRUG

AZD3480 capsules qd, 12 days

Warfarin

Intervention Type DRUG

Warfarin: single dose on day 6

2

Placebo+ warfarin

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Placebo capsules qd, 12 days

Warfarin

Intervention Type DRUG

Warfarin: single dose on day 6

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD3480

AZD3480 capsules qd, 12 days

Intervention Type DRUG

Placebo

Placebo capsules qd, 12 days

Intervention Type DRUG

Warfarin

Warfarin: single dose on day 6

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of signed written informed consent
* Clinically normal physical findings and laboratory values

Exclusion Criteria

* Clinically significant illness or clinically relevant trauma within three weeks before the first dose
* History of clinically significant disease
* Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes